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Introduction:The2018Coffey-HoldenProstateCancerAcademy (CHPCA)Meeting,
“Tumor Cell Heterogeneity and Resistance,”was held in Los Angeles, California from
June 21 to 24, 2018.
Methods:TheCHPCAMeeting is a unique, discussion-oriented scientific conference
convened annually by the Prostate Cancer Foundation (PCF), which focuses on the
most critical topics in need of further study to advance the treatment of lethal
prostate cancer. The 6th Annual CHPCA Meeting was attended by 70 investigators
and concentrated on prostate cancer heterogeneity and treatment resistance.
Results:Themeeting focusedon topics including: recognitionof tumorheterogeneity,
molecular drivers of heterogeneity, the role of the tumor microenvironment, the role
of heterogeneity in disease progression, metastasis and treatment resistance, clinical
trials designed to target resistance and tumor heterogeneity, and immunotherapeutic
approaches to target and overcome tumor heterogeneity.
Discussion: This review article summarizes the presentations and discussions from
the 2018 CHPCA Meeting in order to share this knowledge with the scientific
community and encourage new studies that will lead to improved treatments and
outcomes for men with prostate cancer.
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1 | INTRODUCTION
The Prostate Cancer Foundation (PCF) is the largest non-profit
foundation in the world that funds research focused on improving
the understanding of prostate cancer biology and advancing new
life-extending and life-improving treatments for patients stricken
with the most aggressive forms of this disease. As a critical
supplement to this effort, PCF convenes several scientific confer-
ences every year and has a large program dedicated to facilitating
global knowledge exchange and the development of new collabo-
rations and research initiatives.
For six consecutive years, PCF has convened the Coffey-Holden
Prostate Cancer Academy (CHPCA) Meeting, an annual “think tank”
conference, which gathers ∼75 investigators to discuss the most
critical topics necessary for making a near-term impact on the
understanding and treatment of lethal prostate cancer.1–5 This
meeting is uniquely designed to promote deep and ample discussion
and brainstorming of necessary next steps by structuring sessions into
short talks with lengthy discussion times. This meeting also supports a
major goal of PCF to promote career development of young
investigators by mandating that the organizing committee and
approximately half of attendees be early career investigators. The
CHPCA Meeting follows the discussion-oriented structure of the
former NCI Prouts Neck Meetings on Prostate Cancer,6 and is named
in honor of the prostate cancer research pioneers, Dr Stuart Holden
and the late Dr Donald Coffey.
The 2018CHPCAMeetingwas held from June 21-24, 2018, in Los
Angeles, California, and was themed “Tumor Cell Heterogeneity and
Resistance.” 70 investigators attended, including 45 young inves-
tigators. Talks and discussions centered on critical topics surrounding
the biology of prostate cancer heterogeneity and the impact of
heterogeneity on treatment outcomes, including recognition of tumor
heterogeneity, molecular drivers of heterogeneity, the role of the
tumor microenvironment, the role of heterogeneity in disease
progression, metastasis and treatment resistance, clinical trials
designed to target resistance and tumor heterogeneity, and immuno-
therapeutic approaches to target and overcome tumor heterogeneity.
2 | UNDERSTANDING PROSTATE CANCER
HETEROGENEITY
Prostate cancer exists in a clinical continuum, ranging from low to high
grade disease, localized to metastatic disease, and hormone-sensitive
to castration-resistant disease. The evolution of the disease from one
end of the spectrum to another is associated with continuing changes
in the genome and emergence of new clones and subclones under the
influence of external pressures. There are unique molecular character-
istics involved in cancer cellular processes such as invasion, migration,
and metastasis that can be measured to classify prostate cancer into
subtypes and thesemay define cancer cell vulnerability or resistance to
treatment pressure. Importantly, therapeutic pressures cause cancers
to lose and/or gain molecular alterations as new subtypes emerge due
to new mutations or epigenetic changes.7,8 Additionally, pre-existing
genetic variants with resistance characteristics may only become
evident or dominant due to treatment selection pressure. Tumor
adaptation due to pre-existing genetic variation is likely faster than
adaptation through de novo mutations or epigenetic alterations, as
beneficial mutations are immediately available in the new environment
(ie, treatment), and may also start at higher frequencies.
Numerous questions exist surrounding the biology of tumor
heterogeneity, including a better understanding of which biologic
features of heterogeneity matter for treatment and outcomes, what
are the critical molecular characteristics of heterogeneity, what are the
roles of truncal versus subclonal genomic alterations, and how to
identify relevant rare clones that may later become a dominant,
treatment-resistant form of disease. The non-treatment related drivers
of heterogeneity are also unclear, including the roles for genomic
instability, regional hypoxia, field effects, immune, stromal and other
heterogeneous factors within the tumor microenvironment, and
immune pressure. Understanding how to successfully treat heteroge-
neous disease within a patient is ultimately necessary for developing
cures for advanced prostate cancer.
3 | HETEROGENEITY OF MULTI-FOCAL
PRIMARY PROSTATE CANCER
One of the hallmarks of prostate cancer is that most men harbor
multiple areas or foci of primary disease, which led to the routine use of
sextant biopsies to ensure adequate sampling of the gland.9 It is critical
to accurately identify tumor foci with dominant or aggressive potential
in any given prostate as these sites contribute to the subclonal
complexity of metastatic disease.10,11
Heterogeneity between different tumor foci within the prostate
has been demonstrated.12,13 These issues of prostate cancer
multifocality and multiclonality confound interpretations of tissue-
based genomic and transcriptomic biomarkers and commercially
available prognostic tests, which impact clinical decision making.13,14
While tissue-based markers assessed on low grade disease may
predict the concomitant presence of an undersampled high grade
disease, emerging data from Wei et al13 and Salami et al (unpub-
lished) suggest that they may not predict the presence of an
unsampled high grade disease. Liquid biopsy approaches such as
those based on urine RNA transcripts (eg, TMPRSS2:ERG, PCA3,
SChLAP1) may help circumvent the problems imposed by tumor
multifocality and heterogeneity. Lessons from breast cancer suggest
that no single modality is perfect, but rather that multiple
complementary approaches may be needed.15 In prostate cancer,
the combination of imaging (MRI, PET), liquid biopsy (urine- and
blood-based), and tissue biopsy approaches may provide the best
opportunity to improve early detection of aggressive prostate cancer
by overcoming tumor multifocality and multiclonality issues. While
validation in larger cohorts with long term patient outcomes is
critical, these findings highlight the importance and need for more
comprehensive approaches.
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4 | GENOMIC DRIVERS OF PROSTATE
CANCER DIVERSITY AND TREATMENT
RESISTANCE
Prostate cancer is driven by the activity of the androgen receptor (AR),
a transcription factor of the steroid nuclear receptor family.16 This
seminal finding was originally noted by Charles Huggins in the early
1940s,17 and 80 years later, whole exome and whole genome
sequencing efforts continue to provide new insights into AR biology
and its regulation in prostate cancer.
Alterations that maintain activity of the AR pathway have been
found to drive the vast majority of castration-resistant prostate cancer
(CRPC) cases. Whole-exome and transcriptome sequencing have
found that AR pathway alterations are apparent in∼71% of metastatic
CRPC (mCRPC) cases, primarily AR gene amplifications and muta-
tions.18 Recent whole genome sequencing studies have identified an
expanded role for AR alterations and continued AR activity in driving
CRPC, as tandem duplications of enhancer elements located upstream
of AR that act as critical drivers of AR expression and AR-targeted
therapy resistance were found in 70-87% of CRPC cases, compared
with <2% of primary prostate cancer cases.19–21 These sites are likely
regulated by epigenetic alterations, as the genomic sequencing peak
coincides with H3K27ac signal. Tandem duplications of enhancers of
MYC and FOXA1 were also found to be common,19,21 highlighting the
importance of evolutionally driven enhancers in CRPC. The formation
of tandem enhancers appears to be regulated by proteins critical to
DNA repair, including CDK12.22 Recent studies suggest that bi-allelic
loss of CDK12 may confer sensitivity to checkpoint immunotherapy,
due to increased levels of fusion neoantigens generated by the tandem
duplicator phenotype.22 Clinical trials to directly test this hypothesis
are underway.
Studies have suggested that prostate cancer heterogeneity
emerges early in tumorigenesis and is further selected for by
treatment. A neoadjuvant trial of ADT+abiraterone acetate in localized
high-risk prostate cancer found that while some alterations develop in
response to treatment, some of the same alterations, such as RB1 loss,
may have been present in untreated tumors and selected for by the
treatment.23 Studies comparing matched pre- and post-treatment
cancer tissue are necessary to determine the frequency of this
occurrence. An ongoing study at the National Cancer Institute where
pre-treatment biopsy is obtained using magnetic resonance imaging/
ultrasound (MRI/US) fusion guidance and compared with post-
treatment radical prostatectomy tissue will be informative
(NCT02430480). Preliminary results from this study have identified
some differential characteristics between responders and non-
responders to ADT + abiraterone acetate independent of Gleason
score. Non-respondersweremore likely to have intraductal carcinoma,
have more heterogeneous somatic copy number alterations, and be
ERG-positive. Not surprisingly, intra-person phenotypic heterogeneity
in response was observed in some patients. Imaging features that can
differentiate responders from non-responders in this trial are under
study. The molecular correlates from this study will be insightful.
Further studies are needed to determine what drives the development
of tumor heterogeneity and subclonal evolution during earlier stages of
tumor progression.
There is abundant effort to characterize each individual patient's
cancer genome using DNA and RNA based approaches to identify
drivers of cancer and inform therapy selection.24 Despite initial
optimism, sequencing efforts have led to the discovery of laundry
lists of mutations and alterations which have no functional
consequence, and of “druggable” targets which fail to yield clinically
meaningful results with the administration of targeted therapies.
This suggests that further proteomic25 and epigenomic26 informa-
tion is critical to yield insight into cancer dependencies and improve
the selection of effective treatments. Additionally, rigorous proto-
cols and optimized methods to define informative markers are
needed to facilitate precision medicine treatment efforts in the
larger cancer community.
5 | HETEROGENEITY OF AR-INDEPENDENT
CRPC
Tumor heterogeneity is a large contributor to response or resistance
to AR-targeted therapy. Possible outcomes following AR-targeted
therapy include a durable complete response, or varied levels and
durations of responses followed by resistance through AR-driven or
AR-independent pathways.27 AR-independent/indifferent CRPC
subtypes include neuroendocrine prostate cancer (NEPC) (some of
which still express AR), and subtypes negative for both AR and
neuroendocrine (NE) markers (“double-negative”).28,29 A study by
investigators at the University of Washington and Fred Hutchinson
Cancer Research Center used tumors acquired from rapid autopsies
and found that from 1998 to 2011, over 88% of lethal prostate
cancer cases were AR-positive, 5.4% were AR-negative/NE-positive,
and 6.3% were double-negative. However, from 2012 to 2016,
following the additions of the more potent AR-axis inhibitors
abiraterone acetate and enzalutamide to the prostate cancer
treatment arsenal, the prevalence of AR-negative prostate cancer
among lethal cases dramatically increased, to 13.3% being AR-
negative/NE-positive and 23.3% double-negative.28 These findings
suggest that evolution under treatment pressure is a large
contributor to the development of AR-null prostate cancer
phenotypes. A study by the PCF West Coast Dream team recently
reported that 17% of progressive, mCRPC had the phenotype of
treatment-emergent small-cell neuroendocrine prostate cancer (t-
SCNC).30 Additional studies are necessary to confirm the hypothesis
that the landscape of CRPC phenotypes has changed in response to
more potent AR pathway inhibition, and to better define these
subtypes molecularly and clinically.
Understanding the mechanisms that drive AR-independent
disease progression is critical toward developing more effective
therapies. AR-positive/NE-positive, AR-positive/NE-negative, AR-
negative/NE-positive, and double-negative mCRPC can be
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differentiated by gene expression patterns.28 Double-negative
mCPRC were found to exhibit elevated FGF and MAPK pathway
activity.28 FGF/MAPK pathway blockade had on-target and anti-
tumor effects in double-negative mCRPC patient-derived xenograft
(PDX) models, and FGFR-inhibition was found to synergize with
enzalutamide, supporting the FGF pathway as a driver of AR-therapy
resistance. Other known mechanisms of resistance to complete AR-
pathway blockade include loss of p53, Rb1, and/or PTEN.7 Whether
double-negative mCPRC may be an intermediate/dedifferentiated
point and could transition into NEPC deserves further study.
Preliminary data presented at this meeting indicated that a phenotype
resembling squamous cell carcinoma may also develop in response to
AR blockade. The mechanism of development of this subtype and
potential therapeutic approaches are currently unknown. Altogether,
there is likely a continuum of AR-indifferent and AR-low/null mCRPC
subtypes. The number of possible lineage pathways remains to be
determined.
6 | EPIGENETIC ALTERATIONS IN CRPC
The role of epigenetic heterogeneity in tumor biology and treatment
responses is of critical interest. Studies into epigenetic hot spots
demonstrate that many hypermethylation changes are conserved
between different metastases and are recurrently present across
multiple patients,31 suggesting that these sites have the potential for
producing selectable driver events. One such example is PRAC1, a gene
exclusively expressed in prostate, colon, and rectal tissue (Haffner et al,
unpublished,32). PRAC1 can be epigentically silenced in CRPC and in
vitro and in vivo studies demonstrate that loss of PRAC1 leads to
castrate resistant growth (Haffner et al, unpublished). Whether such
hypermethylation changes may be reversed by treatment or serve as
biomarkers is of question. The relationship between hypermethylation
changes and the genomic background of the tumor also deserves
further study.
While hypermethylation suggests potentially druggable targets,
consequences of hypomethylation may include altering of the immune
milieu.Global lossofepigenetic repressivemarkershave ledto increased
activity of retrotransposons such as LINE1 and ALU1,33 genomic
instability,34 and expression of neoantigens including NY-ESO-1 and
MAGE.35 This has the potential to be therapeutically exploited, as
pharmacologically induced hypomethylation can alter the immune
microenvironment, increase interferon signaling, and improve lympho-
cytic infiltration into tumors.36,37 These effects suggest synergy may be
achieved with hypomethylation-inducing agents and checkpoint
inhibitors, and warrant further study. A constitutive “extreme hypo-
methylation” phenotype with associated profound changes in the
intratumoral immune microenvironment has been recently observed in
testicular germ cell tumors.38 In such hypomethylated tumors,
endogenous retrovirus expression is greatly increased resulting in
enhanced interferon type I responses. This demonstrates a previously
unrecognized link between cancer cell specific epigenetic alterations
and the tumor immune microenvironment.
7 | SYNTHETIC ESSENTIALITY: TARGETING
GENETIC HETEROGENEITY IN PROSTATE
CANCER
Many therapeutic strategies are being explored to target cancer
genetic alterations. In oncogene addiction, cancer cells are physiologi-
cally dependent on the continued activity of oncogenes to maintain a
malignant phenotype.39 Clinical success has been achieved in targeting
oncogenes as exemplified by targeting AR amplification with
enzalutamide. However, there are still many undruggable oncogenes
or tumor suppressor genes. Another concept is synthetic lethality, in
which tumor cells that have lost activity of one molecular pathway
become highly dependent on a second related pathway, which can be
therapeutically targeted.40 For example, clinical success has been seen
with PARP inhibitors in patients with tumors with homologous
recombination deficiency (HRD).41 A similar concept is “collateral
lethality,” in which passenger genomic events in tumor cells can create
unintended vulnerabilities, particularly in the deletion of redundant
essential housekeeping genes.42,43 A related concept is “synthetic
essentiality,” in which genes that may be deleted in some cancers, are
almost always retained in the context of a specific tumor suppressor
deficiency, and may represent therapeutic vulnerabilities.44 Synthetic
essential genes may be identified with the aid of available cancer
genome and clinical databases, by examining for genes that exhibit
mutually exclusive deletion patterns.44 Zhao et al identified the
epigenetic regulator CHD1 as being deleted in some prostate cancers
in a mutually exclusive manner with PTEN.45 CHD1 was further
demonstrated to be a possible therapeutic target in PTEN-deficient
prostate cancer models.45 In PTEN-deficient breast and prostate
cancer, CHD1 is a synthetic-essential gene, which when degraded via
the PTEN-AKT-GSK3β axis, suppressed cell proliferation, and cell
survival.45 Studies to validate whether CHD1 is an active therapeutic
target in PTEN-deficient human cancer may be warranted. Using the
concept of synthetic essentiality, tumor suppressor deficiencies can be
targeted for clinical benefit.
8 | SINGLE CELL PROTEOGENOMICS
Because of the high levels of tumor cell genomic, molecular, and
phenotypic heterogeneity, single cell analyses can greatly enrich
understanding of tumor cell biology and function. Kuhn and colleagues
have developed a high definition single cell analysis workflow to
analyze morphology, gene expression, and genomics of single
circulating tumor cells (CTCs). This technology has been applied to
over 15 000 samples from over 4000 patients with prostate and other
cancers. CTCswere found to have heterogeneousmorphology, belying
the importance of single cell analyses to understand biologies that
correspond with one another and biologies that are exclusive or
incompatible.46 A slide-based approach using time of flight mass
cytometry (CyTOF), which enables subcellular resolution of up to 35
proteomic parameters simultaneously, is now being applied to add
proteomics information to single cell CTC analyses.
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CTCs have been demonstrated to have utility as predictive
biomarkers for treatment responses. The absence or presence of
nuclear AR-V7 in CTCs has been found to be predictive for better
survival if treated with AR-targeted therapy versus taxane chemo-
therapy, respectively, as second line treatment for progressive
mCRPC.47 This test has been commercialized and is now being used
in the clinic.
The Blood Profiling Atlas in Cancer (BloodPAC) Consortium is a
Cancer Moonshot inspired program that aims to accelerate the
development and validation of liquid biopsy assays for various types of
cancer. Three pilot projects are underway to improve and validate
high-throughput liquid biopsy methodologies, including a PCF-funded
project that will determine whether variations in blood collection
protocols, such as sampling intervals, time of day, draw order, fasting
status, and anti-emetics, affect prostate cancer CTC analytical results.
9 | IMAGING APPROACHES FOR
IDENTIFYING AGGRESSIVE PROSTATE
CANCER AND TUMOR HETEROGENEITY
Conventional imaging using computed tomography (CT) has limited
ability to characterize heterogeneity beyond the location of metastatic
lesions. There is great interest in leveraging more advanced imaging
techniques that enable better lesion characterization. Newer imaging
approaches including PSMA PET and multi-parametric MRI have
significantly changed our paradigm for detecting and understanding
prostate cancer heterogeneity. Though primarily designed for
evaluating the location and extent of disease, imaging has the potential
to provide biologically relevant information such as tumor
aggressiveness.
PSMA (prostate specific membrane antigen) is highly and
specifically expressed on the surface of prostate cancer cells, and is
positively correlated with disease progression. PSMA PET has led to
improvement in estimating the burden of disease in primary and
recurrent prostate cancer with high sensitivity and specificity.48,49
Although early data suggests that PSMA PET may be useful for
predicting disease response,50 it is unclear how to interpret the
intensity of PSMA expression in relation to Gleason score, tumor
biology, tumor microenvironment, and androgen dependency. In a
case series of men with metastatic prostate cancer treated with
frontline and salvage chemotherapy, concordance between PSA and
PSMA PET response was reported.51 Although PSMA is expressed on
>90%of prostate cancer cases, expression is linked toAR-signaling and
can be heterogeneous within an individual. PSMA PET may not be
useful in all patients, including thosewithNEPC or ductal carcinoma, as
PSMA expression can be lost on these prostate cancer subtypes. A
study comparing PSMA-targeted 18F-DCFBC PET/CT and 18F-sodium
fluoride (NaF) PET/CT for detection of bone lesions in patients with
metastatic prostate cancer, found that while detection of putative
lesions between the two technologies were largely concordant, the
majority of lesions were detected by one modality but not the other.52
Because NaF PET is an indicator of osteoblastic activity and not a
direct measure of tumor burden, it will be important to understand
how treated lesions versus viable lesions are differentially identified by
thesemodalities. Discordance has also been observed between PSMA-
PET and 18F-FDG PET imaging, further suggesting biological
heterogeneity across different lesions.53 The underlying biology and
clinical implications of this discordance are yet unclear. Prospective
studies are needed to inform how best to change patient management
based on PSMA PET and other imaging findings. PCF has previously
published a report from a working group meeting held on issues
surrounding PSMA as an imaging and therapeutic target; issues
surrounding the heterogeneity of PSMA expression were amajor topic
of discussion.54
Multi-parametric MRI measures a number of different functional
and anatomical features of tissues such as vascularization and diffusion
of water molecules, providing staging and possibly cancer biology
information. In a recent randomized trial of targeted biopsy versus
standard biopsy, the MRI PI-RADS score was found to be correlated
with clinically significant prostate cancer defined as Gleason ≥7 (12%
for PI-RADS 3, 60% for PI-RADS 4, and 83% for PI-RADS 5).55
However, the accuracy of MRI as a predictor of long term oncological
outcomes is unknown. In an unpublished work (n = 612) by Faena and
colleagues at the University of California Los Angeles (UCLA), PI-RADS
on MRI was shown to predict biochemical recurrence, a surrogate for
disease aggressiveness. Additionally, Salmasi and colleagues have
demonstrated that Oncotype Dx GPS correlated positively with PI-
RADS, suggesting that MRI may be providing some biological
information.56 However, the biological basis of cancer visibility on
MRI is poorly understood. In work examining histological appearance
of the tumor, only 17% of lesions with cribriform pattern 4were visible
on MRI.57 A study that compared 49 radiomic features (diffusion
weighted (DWI), Ktrans etc.) to RNA expression data from 17 MRI-
targeted biopsies from six patients found that distinct radiomic
features in the transition and peripheral zones correlated with gene
signatures, suggesting the possibility of a field effect.58
One issuewith DWIMRI is the technical difficulty in implementing
a robust and reproducible sequence across sites. Restriction Spectrum
Imaging (RSI) is a variant of DWI that aims to providemore information
on disease characterization and increase the robustness of the
acquisition.59 Compared to conventional DWI, RSI has been shown
to provide improved characterization of prostate cancer in the intact
setting with improved inter-reader variability. Evaluation in the
metastatic setting has not yet been performed, but understanding
how to evaluate heterogeneity using RSI and other novel imaging
methods including 68Ga-PSMA-11 will be important.
With emerging technologies such as MRI and next generation
sequencing (NGS), we need to rethink the development and detection
of aggressive prostate cancer. Though the most common solid organ
malignancy in men,60 prostate cancer early detection continues to be a
clinical challenge due to tumor multifocality.61 Until recently, prostate
cancer diagnosis was essentially a blind procedure, where a transrectal
ultrasound guided biopsy samples only about 0.04% of the prostate.62
Hence, there is no guarantee that the actual cancer focus is being
sampled using ultrasound guidance. The emergence of prostate MRI,
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however, has facilitated the detection of aggressive prostate cancer
with high sensitivity and negative predictive value.55,63,64 Although
MRI/US fusion prostate biopsy has facilitated the longitudinal
sampling of the same site of cancer, it is still unknown if low grade
prostate cancer progresses to higher grade.65 It is possible that low
grade cancer that “progresses” while on active surveillance may
actually be a second primary.66 Additionally, prostatic intraepithelial
neoplasia (PIN), which is regarded as a precursor of cancer, may
actually be invasive disease.67 Additional studies are needed to
delineate the existence of precancerous lesions and to determine if
and how clonal progression of low to high grade cancer occurs.
10 | TRANSLATING IMAGING OF
HETEROGENEOUS DISEASE TO TREATMENT
Therapeutic success in treating men with prostate cancer is limited by
disease heterogeneity. In trials, patients with higher volume disease
and patients with metastases perform worse when treated with
targeted therapies.68,69 Clonal evolution results in a heterogeneous set
of metastatic lesions within a single patient.11 Nonetheless, patient-
level genomic alterations can predict the response of patients to some
therapies (eg, AR-V7).41,70 Treatment approaches that take into
account disease heterogeneity across metastatic lesions are needed.
One issue limiting our ability to characterize heterogeneity, is the
limited samples that are evaluated from tissue biopsies. Using PET
imaging, we can label therapeutic antibodies and determine the
presence of their target prior to treatment. In breast cancer this has
been studied with trastuzumab, and uptake of 89Zr-trastuzumab prior
to the initiation of therapy predicts for patient level response to
therapy.71 Within the same patient, there can be a wide range of
uptake across metastatic sites.72,73 Improved biomarkers are also
needed to predict responses to immune checkpoint inhibitors, as the
presence of PD-L1/ PD-1 can vary across lesions,74 and presence or
absence of PD-L1/ PD-1 as determined by immunohistochemical
staining is not always predictive of treatment response.75 Approaches
using 64Cu-anti-PD-L1 have been performed in animal models.76 In
first-in-human studies using 89Zr-atezolizumab (anti-PD-L1), uptake
within patients varied ninefold across tumor sites, indicating a wide
range of PD-L1 expression, and results on the relationship between
uptake and patient level outcome are pending (NCT02453984).77 One
issue with antibody-based PET imaging agents is that imaging is best
performed at delayed timepoints (up to 7 days after injection), and
therefore small molecule approaches would be greatly preferred.
Currently there is a preclinical agent that binds to PD-L1 using 18F-
adnectin that has promise in allowing more feasible in vivo imaging of
the heterogeneity of PD-L1.78
Once sites of metastatic disease are localized and characterized,
the question remains about how to treat them. The term oligometa-
static disease was coined to describe patients who have a limited
number of sites of metastatic disease and therefore may be curable.79
With the increased detection of oligometastatic disease using PSMA
PET, the push to treat these lesions using metastasis-directed external
beam radiation therapy has increased.80 Early phase II randomized
trials have demonstrated that metastasis-directed radiation therapy
can prolong ADT-free survival compared to surveillance when using
choline PET/CT to detect sites of oligometastatic disease.81 Another
currently ongoing trial is evaluating the benefit of stereotactic body
radiation therapy (SABR) versus active clinical surveillance in patients
with oligometastatic disease detected by conventional imaging
(NCT02680587).82 All patients on the SABR arm receive a PSMA
PET which is blinded at time of treatment, and locations of recurrence
will be correlated with upfront PSMA PET to determine patterns of
recurrence. These studies will help us to better understand and
optimize the role of targeted radiation therapy in the setting of
oligometastatic disease, and how best to use imaging to identify and
manage oligometastatic disease.
11 | COMPUTATIONAL MODELS TO
FORECAST TUMOR PROGRESSION
Understanding the spatiotemporal pathways of tumor progression will
result in a better understanding of disease biology and has implications
for patient management. For instance, Markov modeling of spatio-
temporal progression pathways based on longitudinal clinical data
found that in approximately 35% ofmetastatic breast cancer cases, the
first site of metastasis is to bone, followed commonly by metastasis to
the chest wall and/or lungs.83 Ultimately however, it is often liver or
brainmetastaseswhich precedemortality,83 suggesting earlier support
of liver health may be beneficial. Different breast cancer subtypes
were also associated with particular pathways of metastatic spread
and temporal progression patterns. For instance, ER-positive disease
typically progresses more slowly than ER-negative disease. Combining
this informationwith data on temporal genomic alterationsmay enable
the development of a “clock” which describes the order and
dependencies of events, and reveal progression bottlenecks and
targeting opportunities. This approach is nowbeing applied to prostate
cancer.
Spatiotemporal mapping using longitudinal clinical data has also
enabled classification of metastatic sites as “spreaders” or “sponges,”
based on the statistical probability of metastatic disease transitioning
from one anatomical site to another. For instance, in breast cancer,
distal lymph nodeswere classified as sponges, andwere not a relatively
significant contributor to further metastatic spread, while in prostate
cancer, lymph nodes acted as both spreaders and sponges.83 The
tendency of lymph nodes in breast cancer to act more as sponges may
help to explain why axillary lymph node dissection in breast cancer has
been found not to improve overall survival.84 Whether or not pelvic
lymph node dissection in prostate cancer impacts survival outcomes is
unclear. In both prostate and breast cancer, bonemetastatic sites were
classified as spreaders while liver sites were classified as sponges.
Studies on metastatic tumor distribution in autopsy patients have
enabled calculations of “entropy,” to indicate the complexity of cancer
progression.85 Compared with 12 other solid tumor types, prostate
cancer had the lowest entropy score, indicating the highest
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predictability of patterns of metastatic spread.85 Approximately 80%
of prostate cancers progressed through the top 30most common two-
step pathways, while only ∼35% of breast cancer progressed through
the top 30 two-step pathways.85
Forecastingmodels andmachine learning techniques are now being
applied to predict individual patient outcomes. Compared with various
statistical models using clinical data, deep learning models integrating
multiple types of data including clinical and liquid biopsy data such as
CTC morphometry, have been able to obtain at least 5-10% improve-
ment in overall performance for predictions of individual overall survival
(OS) and progression free survival (PFS) (Kuhn et al, unpublished). Deep
learning models also performed better than linear or Gaussian models,
when using heterogeneous data (clinical, high definition single CTC
imaging, and CTC enumeration), and were able to make relatively
accurate individual outcome predictions (Kuhn et al, unpublished).
12 | MICROENVIRONMENT: THE CANCER
SWAMPS
The tumor microenvironment (TME) is complex and can consist of a
heterogeneous mix of basal cells, fibroblasts, blood vessels, immune
components, nerves, extracellular matrix, etc, in addition to tumor
cells.86 The makeup of the TME varies greatly from primary to
metastatic cancer sites, and even within the same tissue. It has been
established that there is bi-directional interplay between the tumor
and TME,87,88 however the molecular underpinnings are not well
understood. Many histo-pathological studies have shown that cancer
affects the surrounding tissue, for example bone remodeling allowing
for tumor growth.89,90 Moreover, it has been shown that benign
prostatic hyperplasia (BPH)-associated stroma promotes epithelial
growth.91 However, less is known on a mechanistic level about how
the TME promotes cancer seeding, growth and metastasis. The
crosstalk between the tumor and surrounding tissue can affect cancer
cell behavior and potentially therapeutic responses in patients. Some
key questions include: i) how can the TME promote cancer
progression; ii) how does the TME affect response to different
therapies; iii) what provides a fertile soil for cancer cells to seed and
metastasize; and iv) can the TME be manipulated to create a more
hostile environment for cancer cells? Improved understanding of these
interactions will likely lead to better predictions of therapeutic
responses, as well as novel approaches targeting both the cancer
and the TME to improve patient outcomes.
A first-in-field study investigated how transcriptional patterns in both
tumor and stroma may promote progression of normal prostate to
invasive carcinomaby isolating samples from radical prostatectomy tissue
of benign, PIN and tumor regions with paired adjacent and distant
stroma.92 Gene expression signatures of each region revealed that
adjacent stromal signatures associatedwith tumor grade and outcome. In
fact, stroma adjacent to areas of high Gleason score resembled a “bone
homing”microenvironment, whichmay help to explain the preference for
metastasis to the bone. Further studies are imperative to determine how
altered stromal pathways can promote tumor progression.
A major hurdle in the field has been a lack of preclinical models
to systematically assess tumor-TME interactions. With the develop-
ment and refinement of patient-derived prostate cancer organoid
models,93–96 new opportunities are arising to introduce stromal
factors in these cultures and study their roles in tumorigenesis and
progression. Early studies reveal that introducing stromal cells into
benign prostate organoid cultures promotes organoid branching, a
process similar to organogenesis (Nonn et al, unpublished). Culturing
primary tumor organoids (tumoroids) with prostate stromal cells
improves long-term culturing and alters stromal gene expression
signatures. Questions that now can be addressed include how
stroma can affect tumorigenesis and progression, for example, by
culturing tumor adjacent versus distant benign stroma with normal
or cancer epithelial cells, and studying morphology and other
features. Moreover, epithelial and stromal cells can be specifically
modified to reflect clinical alterations, which will reveal interactions
between the cancer cells and TME that are dependent on their
molecular characteristics.
While organoid culturing has the advantage of being able to
manipulate single (ie, stromal) factors to assess their effect on
tumor growth, this ex vivo approach has limitations. In vivo tissue
recombination approaches could provide a more physiological
context that better mimics the prostate microenvironment.41,97
Human prostatic epithelial cells can be recombined with human
prostatic stromal cells and grafted under the renal capsules of
mice. Manipulating both the stromal and epithelial cells will likely
shed light on interplay between stromal factors and genetic
alterations to promote benign prostate hyperplasia and various
degrees of cancerous growth. These models often give rise to
heterogeneous tumor regions within the graft, which could be
used to identify TME factors that promote aggressiveness and
metastasis.
In order to metastasize, cancer cells have to exit their primary
site and seed a new location in the body. When regarding this
process from an ecological perspective, it is possible that unfavor-
able conditions at the primary site (eg, hypoxia, reduced acidity) may
drive cells to migrate away to find better soil, described as the
optimal foraging theory,98 as opposed to disseminating tumor cells
being actively attracted to other tissues. To study cancer evolution in
response to changing heterogeneous environments in a controlled in
vitro setting requires complex culturing conditions. With this in
mind, an innovative microfluidic device was developed (Evolution
Accelerator99), which allows gradient conditioning of the environ-
ment and can be used for single cell time-lapse microscopy. This
technology enables assessment of how nutrients, therapeutics,
growth factors, cancer versus stromal metabolites, and various TME
components and other factors can affect cancer evolution and
progression.100,101
With the new preclinical models highlighted above and others not
discussed here, such as patient derived ex vivo explant modeling
(PDE),102,103 new methods can be developed to study the bi-
directional crosstalk between tumor and TME. Thorough clinical
assessment of paired tumor and stroma in both primary andmetastatic
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disease will generate new hypotheses for studying roles of stromal
factors in cancer behavior and therapeutic response versus resistance.
Another aspect that should be considered is the immune
component in the TME104: what makes the prostate TME hostile to
anti-tumor immune cells and how can this be overcome to make
immune-based therapy (eg, PD-1 and PD-L1 targeted therapies) more
effective? Some of the answers likely lie in the tumor-TME crosstalk
and thus it is imperative to consider immune signaling and infiltration in
these studies, especially when studying clinical samples. In sum,
current efforts on studying tumor-TME communication in evolving
pre-clinical models combined with clinical studies are poised to reveal
novel interactions and identify new opportunities for therapeutic
intervention to circumvent progression and improve patient
outcomes.
13 | EVALUATING IMMUNOLOGIC
HETEROGENEITY
Multiple cell types, particularly T-cells, are involved in anti-cancer
immune responses. In the tumor immunity cycle, the T-cell receptor
must recognize and engage the peptide-MHC complex on the tumor.
Ideally, T-cells will expand, infiltrate the tumor, recognize tumor cells,
and maintain functionality in the poor milieu of the tumor microenvi-
ronment which tends to diminish immune responses. This allows for
antigen spreading. Effective immunotherapy needs to be able to go
through this cycle—engagement, expansion, excursion, establishment
of ID, and enablement, to be successful.
It is important to understand the heterogeneity of the immune
response and how it changes throughout tumor progression and
during treatment. Strategies for evaluating tumor and immune
heterogeneity and the impact of immunotherapy in the tumor
microenvironment include non-invasive methods such as Immuno-
PET and peripheral blood analyses of immune cell subsets, CTCs,
circulating tumor DNA, and extracellular vesicles (EVs), and invasive
methods (tumor biopsies) that can assess neo-epitopes, tumor
mutational burden, etc. Non-invasive techniques, such as EVs, are
being developed as “liquid biopsies” to help characterize the tumor
microenvironment. EVs can be isolated from blood, are released by
most cell types, and can carry genetic information.105 EVs are being
studied as potential biomarkers and to provide information on the
functional status of the tumor microenvironment. In an ongoing trial
at the NCI evaluating the efficacy of an anti-PD-L1 antibody and a
PARP inhibitor in mCRPC (NCT02484404), EV analysis of 10 patient
responders versus 10 patient non-responders at day 15 found
increased expression of CD45 in responders. Liquid biopsies and
ImmunoPET could also provide less invasive platforms to assess
heterogeneity over time, for instance to evaluate rapid adaptive
responses to immune pressures. In order to understand the impact of
immunotherapy on the tumor microenvironment, it is important to
continue to develop tools to assay for DNA, RNA, and protein using
invasive and non-invasive techniques.
14 | THE ROLE OF TUMOR MUTATIONAL
BURDEN IN ANTI-CANCER IMMUNE
RESPONSES
Increased tumor mutational burden is associated with increased
neoantigen levels and heterogeneity and with better responses to
immunotherapy. In tumor types such as non-small cell lung cancer
(NSCLC), progression-free survival has been found to be significantly
longer with first-line nivolumab plus ipilimumab in patients with high
tumor mutational burden.106 Prostate cancer typically has a
relatively low number of somatic mutations affecting protein-coding
regions, and success with single agent immune checkpoint inhibition
has been limited. However, mutational burden may not be a reliable
biomarker for immune checkpoint inhibitors in all tumors, as some
tumors with low burden of somatic mutations can be immune
responsive.107 In clear cell renal cell carcinoma, tumor mutational
burden was not found to be associated with response to nivolumab,
but rather response was associated with distinct immune-related
gene expression profiles.107 In metastatic renal carcinoma, a
progression-free survival benefit during treatment with bevacizumab
and atezolizumab was associated with high levels of T-effector cell
function and myeloid inflammation.108 Microsatellite instability has
also been associated with responsiveness to immune checkpoint
inhibition, resulting in the FDA's first tissue-agnostic approval of the
anti-PD-1 antibody pembrolizumab in microsatellite instability-high
(MSI-H) or mismatch repair (MMR) deficient solid tumors.109
However, not all mutations are immunologic targets and immune
pressure can result in enrichment for mutations that enable immune
evasion.110 This has been observed in experiments with tumor cells
with KRAS mutations111 and alterations in the JAK family kinases.110
Using an in vitro culture system that simulated the human tumor
microenvironment, tumor cells expressing mutated KRAS were
found to drive conversion of CD4+CD25−T cells into suppressive
Tregs, promoting immune tolerance.111 JAK1 frameshift mutations in
solid tumors were associated with high mutational burden and
microsatellite instability.110 Rather than eliciting greater immune
responses, JAK1 loss of function mutations were associated with
tumor immune evasion through the loss of JAK1-mediated interferon
responses.110 It is also important to consider that responses to
immune checkpoint inhibitors in patients with high mutational
burden are not universal, as was seen in MSI-H prostate cancer
patients.112 Additionally, in locally advanced and metastatic urothe-
lial carcinoma, atezolizumab showed durable activity in a phase II
study in patients who had previously progressed following treatment
with platinum-chemotherapy,113 but in the phase 3 IMvigor211 trial,
atezolizumab was not associated with overall survival benefit versus
physician's choice of chemotherapy in platinum-treated locally
advanced or metastatic urothelial carcinoma with PD-L1 expression
≥5%.114 As evidenced by this trial, PD-L1 expression (or other
checkpoints) is not a universally predictive biomarker. Similarly,
neoantigen vaccine strategies need further investigation, as resident
memory T-cells can vary in different tumors within a patient.115
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15 | DEFINING THE T CELLS THAT
RESPOND TO CHECKPOINT
IMMUNOTHERAPY
While immune checkpoint inhibition has led to impressive responses in
some tumor types, only a subset of tumor infiltrating immune cells
express immune checkpoints. The clinical response to immune
checkpoint blocking antibodies depends also on the nature of pre-
existing immunity and the tumor microenvironment. A better
understanding of the types and features of immune cells within
tumors will reveal strategies to improve responses to immunothera-
pies, and reveal how underlying immune biology contributes to disease
progression and treatment responses.
T-cell infiltration has been evaluated in a range of tumors including
renal cell, prostate, and bladder. The proportion of cells in the tumor
that are CD8+ T cells can vary widely within and across these different
tumor types. In renal cell carcinoma, disease progression following
surgery was slower in patients with higher frequencies of tumor-
infiltrating CD8+ T cells, independent of tumor stage (Kissick et al,
unpublished), supporting a role for CD8+ T cells in limiting cancer
progression. Prostate tumor tissues however, had over threefold lower
CD8+ T cell numbers than renal cell carcinoma tissues, as well as lower
numbers than all other cancer types evaluated (Kissick et al,
unpublished).
In order to optimize the use of checkpoint immunotherapy in
prostate cancer, it will be important to identify T cell subsets that can
be elicited with checkpoint inhibitors (most likely those that express
checkpoints), and develop biomarkers that can indicate likelihood of
response. In a model of chronic infection with lymphocytic chorio-
meningitis virus (LCMV), CD8+ T cells that proliferated in response to
programmed cell death 1 (PD-1) blockade were found to be composed
almost entirely of an antigen-specific PD-1-expressing subset.116
TCF7+ T cells are a subset of CD8+ cells which have a proliferative
stem cell-like capacity, that normally reside in lymphoid organs in
contact with antigen presenting cells (APCs) and when activated,
generate effector cells which express TIM3 and other terminally
differentiated markers. In human tumors, TCF7+ CD8+ T cells were
found to correlate with levels of total CD8+ T cells (H. Kissick et al,
unpublished), suggesting theymaintain the T-cell population in tumors,
and might be essential for response to immune checkpoint inhibition.
The levels of antigen-presenting dendritic cells (MHCII+) also
correlated with the levels of TCF7+ CD8+ T cells. As the interaction
between T cells and APCs is a driving factor in T cell responses, and is
regulated by expression of immune checkpoints, there are significant
implications for the co-localization of these populations within tumors
and tumor niches in determining responses to checkpoint immuno-
therapy. The relatively low levels of critical anti-tumor immune
populations in prostate cancer suggests a failure of immune
components to effectively communicate and induce T cell prolifera-
tion. Future studies must aim to identify critical immune populations,
as well as detail the temporal, spatial, and numeric requirements for
these cell types in driving responses to immune checkpoint blocking
antibodies.
16 | ROLE OF TISSUE RESIDENT MEMORY T
CELLS IN TUMOR HETEROGENEITY AND
RESPONSE TO CHECKPOINT
IMMUNOTHERAPY
Single-cell mass cytometry performed to characterize the tumor
microenvironment in melanoma found that immune checkpoints were
predominantly expressed by a small subset of CD4+ and CD8+ T-cells
within the tumors, which were enriched for a tissue-resident memory T-
cell (TRM) phenotype.
115 TRMs are a distinct subset ofmemory T-cells that
reside within peripheral tissues, do not recirculate, and provide immune
surveillance. A marker of TRM is CD69, and while this is also a marker for
activated T-cells, in TRM cells it is implicated in tissue retention.
115 The
non-circulatory, tissue-retentiveproperties that typicallycharacterizeTRM
cells suggest that different T cell clones may inhabit different individual
metastatic lesions within a patient and contribute to inter-lesional
heterogeneity. To address this question, TCR sequencing was performed
onmultiplemetastatic lesionsbiopsied from individualmelanomapatients
at the same time to compare theT-cell repertoire at different sites.115 The
abundance of different T-cell clones was found to substantially vary
across thedifferentmetastatic sitesof individual patients, and20%to60%
of TCRs were found to be unique to individual lesions. Data suggest TCR
diversity between metastatic sites was derived from the tumor TRM cells.
Interestingly, whole-exome sequencing of the same metastatic sites
revealed that the inter-lesional diversity of TCRs was greater than the
diversity of expressed somatic protein-altering single nucleotide variants
(SNVs) or predicted HLA-binding epitopes.115 These data suggest TRM
cells create genomically distinct immune microenvironments without
equilibration between metastatic sites.
These findings have significant implications for monitoring
responses to immunotherapy and suggest mechanisms that may
contribute to observed heterogeneity of inter-lesional responses.
Response andprogressionmaybe site-specific andmultiplemechanisms
may existwithin a patient. Antigen-specificity aswell as longevity of TRM
cells may contribute to the durability of responses seen. Enhancing the
frequencies of TRMs in tumors, targeting truncalmutations, and targeting
shared and essential antigens may be potential strategies to addressing
intra- and inter-lesional heterogeneity. Pluripotencygenes andstemness
antigens may be targets to overcome tumor heterogeneity,117
particularly in vaccine development. In addition, tumor-infiltrating
lymphocyte (TIL) based therapies may benefit from harvesting T cells
from multiple sites of disease. The presence and role of TRM cells in
prostate cancer remains to be determined.
17 | CLINICAL TRIALS DESIGNED TO
ADDRESS RESISTANCE AND
HETEROGENEITY
The past decade has seen an explosion of treatments with diverse
mechanisms of action for patients with prostate cancer including
targeted hormonal therapy, chemotherapy, and immunotherapy.
Earlier use of agents such as docetaxel and abiraterone acetate in
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disease history is resulting in changes in disease biology and patterns of
treatment resistance. As a result of the transforming standard of care,
there is a need for context-focused biomarker-driven trials that enable
the practice of precision medicine. Precision medicine aims to more
appropriately select targeted therapies able to overcome resistance
and heterogeneity, while also avoiding therapy exposure and potential
toxicity in patients unlikely to derive benefit.
One challenge with delivering more precise care is consistency
in defining predictive biomarkers. Two randomized phase II studies
evaluating abiraterone acetate with or without PARP inhibition
exemplify this challenge.118,119 In a post-hoc analysis, Hussain and
colleagues found that patients with DNA repair deficient tumors had
improved outcomes compared to DNA repair wild-type patients.118
In this study, DNA repair deficiency status was determined from
baseline metastasis tumor biopsy using whole exome and tran-
scriptome sequencing.118 In a separate trial, Clarke and colleagues
evaluated abiraterone acetate with or without olaparib and
attempted to investigate whether any added benefit of olaparib
was affected by homologous recombination status.119 The bio-
marker subgroup analysis used to define homologous repair status
was a composite analysis based on three different genomic assays,
including a tissue-based assay performed on archival primary tumor
tissue, a plasma-based assay for circulating tumor DNA, and a blood-
based germline assay performed on circulating leukocytes.119
Unfortunately, homologous recombination status could not be
determined conclusively in 61% of patients.119 While no association
was observed between homologous recombination status and
treatment responses, this study was not appropriately designed
and the biomarker was not clearly defined to adequately answer this
question.119
Another unmet need in the field is the definition of early stage
biomarkers of response which are clinically meaningful. A recent study
evaluated individual patient data, week 13 CTC response, and PSA
response endpoints from five prospective randomized phase III trials
that enrolled a total of 6081 patients.120 CTCnonzero at baseline and 0
at 13weeks and CTC conversion (≥5 CTCs at baseline, ≤4 at 13weeks)
demonstrated the highest discriminatory power for overall survival and
were found to represent clinically meaningful and robust response end
points for early-phase metastatic CRPC clinical trials.120
For patients with localized disease, the treatment paradigm has
not significantly changed over the past several decades. While radical
prostatectomy is a curative treatment option for a substantial number
of patients, patients with high-risk disease are at increased risk of
disease recurrence and death from prostate cancer despite treat-
ment.121 Consequently, novel strategies utilizing multimodality
therapy are warranted to improve cure rates and long term outcomes
for high-risk patients. Neoadjuvant systemic therapy is utilized for the
treatment of many solid tumor malignancies and has the potential to
offer local and systemic disease control.122,123 Historically, neo-
adjuvant ADT led to improvements in the rate of organ-confined
disease and decreased positive surgical margins.124 However, earlier
studies failed to consistently evaluate recurrence rates and long term
outcomes. More contemporary phase II neoadjuvant studies have
evaluated more potent therapies targeting the AR signaling axis.
Collectively, these studies have demonstrated a 10% pathologic
complete response rate and 30% rate of minimum residual disease
following six months of potent AR-targeting therapy.125–127 A pooled
retrospective analysis of post-prostatectomy outcomes from patients
enrolled on these studies demonstrated that at a median follow-up of
3.4 years, no patient with minimal residual disease experienced a
disease recurrence.128
After a series of contemporary randomized phase II studies, we are
at a critical cross road that warrants testing of neoadjuvant AR-
targeted therapy in the context of a phase III study. However, many
questions remain regarding the design of such a trial with regards to 1)
patient selection for enrollment; 2) use of a biomarker to enroll patients
most likely to derive benefit from intensive hormonal therapy; 3)
treatment arms and inclusion of a radical prostatectomy alone arm; and
4) selection of the appropriate primary endpoint and validation of
minimum residual disease as a surrogate of metastasis-free and overall
survival. Additional questions remain regarding the use of the
neoadjuvant paradigm to explore PARP inhibitor based therapies for
patients with germline DNA repair aberrations.
For patients with non-castrate disease, the paradigm is shifting,
with new objectives focused on eliminating all disease in patients
previously deemed incurable with any single treatment modality. The
METACURE trial (NCT03436654) which opened for accrual in
June 2018 will enroll patients with high-risk localized disease, low
volume metastatic disease, and biochemically recurrent disease with
evidence of metastases on novel PET imaging. Patients will be treated
with intense ADT and aggressive locoregional treatment including
radical prostatectomy with or without lymph node dissection and/or
radiation therapy. The primary endpoint will be rates of pathologic
complete response and minimum residual disease.
Studies have explored mechanisms of resistance to intense
androgen deprivation with leuprolide, abiraterone acetate and
prednisone. Residual prostate cancer foci in radical prostatectomy
specimens from patients treated with intense AR-targeted therapy
were subjected to immunohistochemistry (n = 49) and whole exome
and transcriptome sequencing (n = 18).23 Residual tumors demon-
strated reduced but persistent nuclear AR and PSA expression.23
Additionally, Ki-67 proliferation was reduced and correlated
negatively with AR activity and positively with decreased RB1
expression. RB1 genetic alterations were enriched in cases treated
with intense AR-targeted therapy compared to prostate cancer cases
from The Cancer Genome Atlas.23 In 15 cases where more than one
tumor focus was microdissected, whole exome sequencing con-
firmed common clonality, however molecular alterations unique to
each focus were also identified and reflect subclones found in
metastatic CRPC specimens.23 Studies investigating mechanism of
response and resistance to intense AR-targeted therapy with
leuprolide, enzalutamide, abiraterone acetate and prednisone are
currently underway. Collectively, these data shed light on mecha-
nisms of resistance to intense neoadjuvant AR-targeted therapy.
Biomarkers to identify patients most likely to benefit from this
treatment strategy are needed.
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18 | DISSECTING MECHANISMS OF
RADIATION RESISTANCE
Prostate cancer is generally a radiation-sensitive disease, and is
responsive to treatment with external beam radiotherapy, brachy-
therapy, and radionuclides. However, radioresistance in prostate
cancer poses a major barrier to successful treatment. Radioresistance
is thought to be multifactorial, ranging from intrinsic tumor
heterogeneity and cell resistance to environmental factors such as
hypoxia, and both the DNA damage repair pathway and the immune
environment are thought to play important roles. Targeting these two
pathways are potential avenues to counter radioresistance.
The interplay betweenDNAdamage repair (DDR) pathways andAR
signalingmayplayan important role in the sensitizationand resistance to
ionizing radiation. Clinical observations suggest that the AR pathway
may modulate the response to radiotherapy. Several large randomized
trials have shown that addition of ADT to radiotherapy improves
disease-free and overall survival in patients with prostate cancer,
particularly those with high risk disease.129–131 The biologic under-
pinnings of this effect were not initially well understood, but several
studies have begun to elucidate this mechanism. A study by Goodwin
etal. demonstrated thatDNAdamage through ionizing radiation induces
AR activity, and in turn, AR induces genes required for DNA damage
repair.132 Suppression of AR activity enhanced the response to DNA
damage both in vitro and in vivo, suggesting a rationale for the observed
clinical benefit of ADT in conjunction with radiotherapy. Using a CRPC
model, Polkinghorn et al similarly showed that second-generation anti-
androgen therapy downregulated DDR genes.133 Prostate cancer cell
lines treated with ionizing radiation plus androgens had enhanced DNA
repair, while anti-androgens caused increased DNA damage, likely
throughdecreased classical nonhomologous end-joining, anddecreased
clonogenic survival. DDR gene mutations are common in prostate
cancer, and these may serve as biomarkers for targeted treatment.41
However, an important point is that not all DDR genes or genetic
variants are equal, and will differently impact sensitivity to radiation or
targeted therapies. The functional impact of various DDR alterations in
prostate cancer needs further elucidation.
The immune environment also plays a role in sensitivity and
resistance to radiotherapy. Radiotherapy can enhance anti-tumor
immunity through several mechanisms. Following irradiation, there is
an increase in DNA damage, which leads to an increase in type I
interferon (IFN) and induction of the adaptive immune response.134,135
Studies show that CD8+ T cells are required for anti-tumor effects of
radiotherapy.134 In murine models, anti-PD-1 antibodies can enhance
antigen-specific cytokine release after radiotherapy.136 Several ongoing
trials are testing the anti-tumor effects of PD-1 inhibitors combinedwith
SBRT. A phase II trial in non-small cell lung cancer is testing whether
additionof SBRT toonemetastatic site prior topembrolizumab improves
outcomes compared to pembrolizumab alone (NCT02492568). Prelimi-
nary results show greater overall response rates at 12 weeks in the
combination arm (41%vs 19%), as well as greater PFS (HR 0.55 [CI 0.31-
0.98], P = 0.04) (Theelen et al, ASCO 2018, Abstract 9023).
Paradoxically, radiation can also induce immunosuppressive
responses. Radiotherapy can induce PD-L1 expression through
inflammatory cytokines, and can stimulate tumor pro-survival mecha-
nisms. Radiotherapy can also generate chemotactic signals that recruit
infiltration of myeloid derived suppressor cells (MDSC) and regulatory
T cells.137,138 One promising strategy to modulate suppressive
immunity and decrease radioresistance involves targeting MDSCs.
The STING/IFN pathway can enhance suppressive inflammation by
recruiting MDSCs in part via CCR2, a receptor for monocyte
chemoattractant proteins.139 Addition of anti-CCR2 antibodies
alleviates immunosuppression following activation of the STING
pathway and can enhance the effects of radiotherapy in mice.139
Thus, blocking negative regulators of immunity may be a promising
strategy to improve local radiotherapy.
19 | THE METASTATIC PROSTATE CANCER
PROJECT
One of the challenges of studying patient tumor samples to better
understand resistance and heterogeneity is that only 5% of cancer
patients in the United States are enrolled in clinical trials and 85% are
treated in the community setting.140 In the modern technology era,
social media platforms provide a new opportunity to engage cancer
patients and directly partner with them in research focused at
understanding diversity within prostate cancer populations. The
Metastatic Prostate Cancer Project (www.mpcproject.org) is a
nationwide genomic research study for men with advanced or
metastatic prostate cancer. The purpose of the platform is to
generate a comprehensive database for clinical and genomic data
that will be shared with the entire research community to accelerate
discoveries in the field of prostate cancer research. This project was
launched in collaboration with multiple advocacy partners in
January 2018 and to date over 500 men have joined across the
United States and Canada.
20 | CONCLUSION
The discussions at the 2018 CHPCA Meeting were productive and
dynamic, with approximately 300 questions asked over 36 talks. The
knowledge exchanged at this meeting through presentations, discus-
sion, and this review article, will promote improved understandings on
the mechanisms and consequences of prostate cancer heterogeneity
and hopefully inspire new studies to improve prostate cancer
treatment and avoid heterogeneity-driven treatment resistance and
lethal disease progression.
The theme of the 2019 CHPCA Meeting will be: “Optimizing &
Accelerating Precision Medicine for Prostate Cancer.”
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